Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    Country filter
      News Type filter
        Company filter
          Product Type filter
            Deal Size filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Novartis Pharmaceuticals Corporation

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWITZERLAND Switzerland

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              Boston Pharmaceuticals Licenses NASH Development Candidate from Novartis

              Contact the Supplier

              Lead Product(s): BOS-580

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: BOS-580

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Boston Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement September 01, 2020

              Details:

              Under the terms of the agreement, Boston Pharmaceuticals will license worldwide development and commercial rights to the drug candidate BOS-580, for the treatment of Non-Alcoholic Steatohepatitis (NASH) from Novartis.

              Altimmune

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              Altimmune Successfully Completes Multiple Dose Toxicity and Toxicokinetic Studies Of ALT-801 For The Treatment Of NASH

              Contact the Supplier

              Lead Product(s): ALT-801

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ALT-801

              Highest Development Status: Preclinical Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 01, 2020

              Details:

              The Company believes the data provide clear validation of previously observed pharmacodynamic effects of ALT-801 and pave the way for the anticipated Phase 1 single and multiple ascending dose clinical trials following submission of a clinical trail application in Australia.

              Altimmune

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              Altimmune Announces Data Presentation on ALT-801

              Contact the Supplier

              Lead Product(s): ALT-801

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ALT-801

              Highest Development Status: Preclinical Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 26, 2020

              Details:

              ALT-801 demonstrated statistically superior reductions (p ≤ 0.05) in body weight, liver weight, plasma ALT, liver triglycerides and cholesterol, plasma cholesterol, NAFLD activity scores, and fibrosis markers compared to semaglutide.

              TransThera Biosciences

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CHINA China

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              LG Chem Life Sciences and TransThera Biosciences Ink License Agreement for Treatment of NASH

              Contact the Supplier

              Lead Product(s): TT-01025

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TT-01025

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: LG Chem

              Deal Size: $350.0 million Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement August 18, 2020

              Details:

              Under the terms of the agreement, LG Chem will obtain exclusive worldwide rights, except Greater China region and Japan, to develop and commercialize TT-01025.

              EpiPharm

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWITZERLAND Switzerland

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              CalciMedica Enters Research Pact with EpiPharma to Discover and Develop CRAC Channel Inhibitor Therapies

              Contact the Supplier

              Lead Product(s): CM5480

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM5480

              Highest Development Status: Preclinical Product Type: Undisclosed

              Partner/Sponsor/Collaborator: CalciMedica

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration July 21, 2020

              Details:

              CalciMedica to use EpiPharma’s state-of-the-art Pre-clinical Drug Testing and Diagnostics Laboratory Platform to accelerate the discovery and development of CalciMedica’s CRAC channel inhibitor novel drug pipeline.

              Lamassu Pharma

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              Lamassu Pharma Receives Prestigious $1.5 Million NIH SBIRP Grant to Support Further Development of its Novel Therapy for Acute Pancreatitis

              Contact the Supplier

              Lead Product(s): RABI-767

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: RABI-767

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: National Institute of Health

              Deal Size: $1.5 million Upfront Cash: Undisclosed

              Deal Type: Funding July 14, 2020

              Details:

              The SBIR grant will be used for further development of company's lead therapeutic compound, RABI-767, a novel small molecule lipase inhibitor licensed from the Mayo Foundation for Medical Education and Research.

              Acquist Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              Acquist Therapeutics Expands Patent Portfolio for Novel Small Molecules, Receives Fourth U.S. Composition Patent

              Contact the Supplier

              Lead Product(s): ACQT1127

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 21, 2020

              Details:

              The patent covers compounds that are intended to help patients with gout, NASH (nonalcoholic steatohepatitis), and other illnesses.

              MAX BioPharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              MAX BioPharma Announces Key Update to its Liver Fibrosis Program

              Contact the Supplier

              Lead Product(s): Oxy210

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 03, 2020

              Details:

              Oxy210 was found to significantly inhibit development of fibrosis in a humanized mouse model of NASH that involves progressive inflammation, fat deposition and fibrosis in the livers of these mice.

              Hepion Pharmaceuticals

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              Anti-Fibrotic Activity of Hepion Pharmaceuticals’ CRV431 Shows Potential to Extend to Multiple Organs and Fibrotic Diseases

              Contact the Supplier

              Lead Product(s): CRV431

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 19, 2020

              Details:

              In vitro studies showed that CRV431 can decrease production of the extracellular matrix molecules, collagen and fibronectin, from fibroblastic cells derived from five different organs.

              PharmaCompass__DigitalAd